Resources
The National Pharmaceutical Council (NPC) is a health policy research organization dedicated to the advancement of good evidence and science, and to fostering an environment in the United States that supports medical innovation.
Filter by:
Topic
Topic
- Accountable Care Organizations
- Alternative Payment Models
- Biopharmaceutical Innovation
- Bundled Payments
- Clinical Pathways
- Decision Frameworks
- Elements of Value
- Evidence for Decision Making
- Formulary/Benefit Design
- Formulary Development
- (-) Good Practices for Evidence
- (-) Health Care Quality Measures
- Health Spending
- Health Spend Management
- High-Deductible Health Plans
- Impact on Outcome & Spending
- (-) Individual Treatment Effects & Personalized Access
- IRA Implementation
- Low-Value Care
- (-) Pandemic Response
- Patient Cost Sharing
- Paying for Cures
- Policy & Regulatory Barriers
- Real-World Data
- Real-World Evidence
- Regulatory Barriers & Challenges
- Understanding Health Spending
- Utilization Management & Step Therapy
- Value-Based Contracts
- (-) Value-Based Insurance Design
- Value Assessment
- Value Assessment Frameworks
- Value Assessment Methods
Resource Type
Resource Type
Display Only
Showing 78 Results
Improving Patient-reported Measures in Oncology: A Call to Action
This study explores the current landscape of oncology patient-reported measures (PRMs), which are tools that capture patients’ voices related to their care experience and outcomes.
How Can Payers Advance Patient-reported Measures in Oncology, and Why Should We Care?
A peer-reviewed study describes the current state of patient-reported measures and patient-reported performance measures in oncology, the barriers to implementation, and actionable recommendations…
Improving Transparency to Build Trust in Real-World Secondary Data Studies for Hypothesis Testing—Why, What, and How Recommendations and a Roadmap from the Real-World Evidence Transparency Initiative
A position paper by the RWE Transparency Initiative describes a plan for improving the transparency of the research process and making registration of real-world evidence study methods easier…
It’s Time to Talk About COVID-19 Prices: Webinar Recap
A summary with video clips from the robust discussion about the societal value and pricing of potential COVID-19 treatments and incentives for current and post-pandemic medical innovation.
Ensuring Care for Vulnerable Populations
NPC President and CEO Dan Leonard discusses how the COVID-19 pandemic has highlighted the persistence of barriers that hamper access to health care for many, especially those in vulnerable…
NPC Comments on CMS Best Price and Barriers to Value-Based Arrangements
NPC outlines how Medicaid Best Price poses a barrier to implementing value-based arrangements and hinders innovation in payment and delivery systems, which can make it difficult for patients to…
A Path of Her Own: Salama Freed, 2020-22 NPC/Duke-Margolis Health Policy Fellow
Salama Freed, PhD, has always wanted to learn about the inner-world of health policy – who shapes it, what drives it and how it gets done. She believes that her path to this experience is through the…
Webinar: It's Time to Talk About COVID-19 Prices
This 2020 webinar brought together experts to discuss pricing, the pandemic and providing incentives to encourage continued innovation.
Sustainable Solutions for Patients’ Sake
Blasine Penkowski, Chair of NPC's Board of Directors, proposes some guiding principles on how we can move toward a post-COVID world and build a more resilient system where patients have the care they…
Ready, Fire, Aim: How Not to Approach COVID Pricing Discussions
NPC raises concerns about various approaches to considering pricing for COVID-19 treatments.
Do Patient Preferences Align with Value Frameworks? A Discrete-Choice Experiment of Patients with Breast Cancer
The study assessed patient preferences for aspects of breast-cancer treatments to evaluate the usual assumptions in scoring rubrics for value frameworks.
Evolution of the AMCP Format for Formulary Submissions: Yesterday, Today and Tomorrow
The ongoing development of vaccines and treatments for COVID-19 is raising hopes as the world awaits the return to a normal way of life. But as seen in the past decades in the fight against cancer,…
NPC in Health Affairs: It's Time to Talk COVID-19 Treatment Prices
In an article on the Health Affairs Blog, National Pharmaceutical Council Chief Science Officer Dr. Robert Dubois considers questions about COVID-19 treatments and prices and lays out a roadmap to…
Will the Pandemic Provide the Push for Positive Change?
NPC President and CEO Dan Leonard considers the COVID-19 pandemic and its impact on our health care system, as well as whether we’ll see continued innovation in how we access, administer and pay for…
Valuing Innovation in the Current and Post-Pandemic World
Biopharmaceutical industry experts gathered for a panel discussion at the eyeforpharma Virtual Conference to explore how the value of innovation, productivity and preparedness might change as a…
In Social Distancing, Finding Closeness in Community
In a video, National Pharmaceutical Council President and CEO Dan Leonard discusses social distancing and the importance of community during the COVID-19 pandemic.
What's Really Behind Discrepancies in Coverage Decisions?
National Pharmaceutical Council President and CEO Dan Leonard discusses research that uncovers the reasons for discrepancies in coverage decisions.